Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT02981303
Title Study of Imprime PGG and Pembrolizumab in Advanced Melanoma and Triple Negative Breast Cancer
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors Biothera

triple-receptor negative breast cancer



Pembrolizumab + PGG beta-glucan

Age Groups: adult | senior
Covered Countries USA

No variant requirements are available.